Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S45-S52 , March 2004

Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension

References 

  1. The advanced glaucoma intervention study (AGIS) . 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429–440
  2. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743–1752
  3. Boger WP. Short-term “escape” and long-term “drift.” The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol. 1983;28(Suppl):235–242
  4. Brandt JD, VanDenburgh AM, Chen K, Whitcup SM. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial. Ophthalmology. 2001;108:1023–1031 discussion 1032
  5. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 1996;103:1916–1924
  6. Collaborative Normal-Tension Glaucoma Study Group . Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487–497
  7. Heijl A, Leske MC, Bengtsson B, et al.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279
  8. Higginbotham EJ, Schuman JS, Goldberg I, et al.  One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286–1293
  9. Kass MA, Heuer DK, Higginbotham EJ, et al.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713 discussion 829–30
  10. Leske MC, Heijl A, Hussein M, et al.  Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48–56
  11. Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Ophthalmology. 2000;107:1171–1177
  12. Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45(Suppl 4):S361–S368
  13. Steinert RF, Thomas JV, Boger WP. Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol. 1981;99:100–103
  14. Stjernschantz JW, Albert DM, Hu DN, et al.  Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol. 2002;47(Suppl 1):S162–S175
  15. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41(Suppl 2):S129–S138

☆ This study was sponsored by Allergan Inc. Dr. Cohen is a consultant for Allergan Inc, and he has received clinical research support from Allergan Inc. Dr. Gross is a consultant to Alcon, Allergan, and Pfizer; he has received research funding and honoraria for speaking engagements from Alcon, Allergan, and Pfizer. Dr. Cheetham is an employee and share-holder of Allergan Inc. Dr. VanDenburgh is an employee of Allergan Inc. Paula Bernstein is an employee of Allergan Inc. Dr. Whitcup is an employee of Allergan Inc.

PII: S0039-6257(03)00194-2

doi: 10.1016/j.survophthal.2003.12.019

Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S45-S52 , March 2004

Article Tools

* Image Usage & Resolution